Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Fractyl Health, Inc. ( (GUTS) ) is now available.
Fractyl Health has announced positive initial clinical results from its REVEAL-1 program, demonstrating weight maintenance in the first patient following GLP-1 drug discontinuation and the Revita procedure. The company reports significant progress in its REMAIN-1 pivotal study, which focuses on weight maintenance post-GLP-1 therapy, indicating strong demand and interest from patients and physicians. These developments suggest Revita may offer a promising long-term solution for weight maintenance without the need for ongoing drug therapy, marking a transformative step in treating obesity and metabolic diseases.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a metabolic therapeutics company focused on pioneering innovative approaches for treating metabolic diseases, including obesity and type 2 diabetes. The company aims to transform treatment from chronic management to durable, disease-modifying therapies targeting organ-level root causes. Fractyl Health’s lead product candidate, Revita, is designed to remodel the duodenal lining to reverse damage caused by chronic high-fat and high-sugar diets, which are root causes of metabolic disease.
YTD Price Performance: -13.15%
Average Trading Volume: 341,095
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $88.98M
See more insights into GUTS stock on TipRanks’ Stock Analysis page.
